The United States biopharmaceutical industry continues to innovate and discover critical solutions for our toughest health challenges such as the COVID-19 pandemic. America’s global leadership has not been by chance, but rather the result of a well-planned effort to facilitate innovation by incentivizing and protecting inventors and supporting collaboration between and among the public and private sectors.
Americans appreciate industry’s role in advancing innovation. In fact, 62 percent of Americans viewed the industry positively in February – a number 30 points higher than in January 2020. Further, 77% agree that keeping a strong American biopharmaceutical industry is a matter of national security to protect us against the next pandemic.
But how did we get here? Consider current public sentiment in the U.S. and how it ties back to policies and investments put in place – in some cases – more than 40 years ago.
87% of Americans agree the coronavirus pandemic has shown how important it is for drug companies to make significant investments in research and development, according to a Public Opinion Strategies internal poll late last year.
The Harris Poll noted fear about the vaccine rollout being too slow dropped from 47% in January to 36% in March. Among the likely contributing factors is the biopharmaceutical’s ability to leverage advanced manufacturing capabilities that have accelerated production and distribution.
The U.S. system of developing medicine is unique – it relies on a mix of private sector, public sector and research institutions working together. While not perfect, a dedicated set of actions to invest in innovation has helped the U.S. biopharmaceutical industry become a true strategic asset domestically – one that drives innovation with the ability to effectively address major crises, as with COVID-19. Data shows that Americans want a strong biopharmaceutical industry – supporting policies to facilitate a strong innovation ecosystem will further U.S. leadership and lead to a positive impact on patients worldwide.